PSNL
$14.04
$-0.50 (-3.47%)-3.47%
ClosedLoading chart...
IndexN/A
Market Cap1.50B
Enterprise Value0.63B
Income$-0.02B
Sales$0.02B
EmployeesN/A
P/E-12.88
P/S10.20
P/B2.72
P/C-8.94
EV/EBITDA-8.82
EV/SalesN/A
EPS (ttm)-1.09
EarningsN/A
Gross Margin22.65%
Oper. Margin-126.43%
Profit Margin-116.69%
Volume1.04M
Shs Outstand0.11B
Change-2.64%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.61M | $73.48M | $65.05M | $85.49M | $78.65M | $65.21M | $37.77M | $9.39M |
| Cost of Revenue | $57.79M | $55.27M | $51.70M | $53.84M | $58.53M | $43.13M | $25.97M | $11.74M |
| Gross Profit | $26.82M | $18.21M | $13.35M | $31.66M | $20.11M | $22.08M | $11.80M | $-2.34M |
| Gross Margin | 31.70% | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Operating Expenses | $95.09M | $128.14M | $128.88M | $97.01M | $62.26M | $44.50M | $25.57M | $19.82M |
| Operating Income | $-68.27M | $-109.94M | $-115.53M | $-65.35M | $-42.15M | $-22.42M | $-13.77M | $-22.16M |
| Operating Margin | -80.68% | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Net Income | $-81.28M | $-108.30M | $-113.31M | $-65.23M | $-41.28M | $-25.08M | $-19.89M | $-23.60M |
| Net Margin | -96.06% | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS (Basic) | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.20 | $-1.39 | $-0.91 | $-1.08 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $270.27M | $225.10M | $292.70M | $396.53M | $244.84M | $157.29M | $41.67M | $33.56M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $67.31M | $95.66M | $74.56M | $86.23M | $49.90M | $50.60M | $148.06M | $126.17M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $202.96M | $129.44M | $218.14M | $310.30M | $194.94M | $106.69M | $-106.39M | $-92.60M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $202.96M | $129.44M | $218.14M | $310.30M | $194.94M | $106.69M | $-106.39M | $-92.60M |
| Total Liabilities & Stockholders Equity | $270.27M | $225.10M | $292.70M | $396.53M | $244.84M | $157.29M | $41.67M | $33.56M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-81.28M | $-108.30M | $-113.31M | $-65.23M | $-41.28M | $-25.08M | $-19.89M | $-23.60M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-45.15M | $-56.26M | $-70.23M | $-70.83M | $-42.65M | $-18.07M | $5.57M | $290.00K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AIGlobeNewswire Inc. PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to TempusGlobeNewswire Inc. Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?The Motley Fool Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to TempusGlobeNewswire Inc. Personalis (PSNL) Q2 Revenue Falls 24%The Motley Fool From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in MedicineBenzinga Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest TechnologyGlobeNewswire Inc.
Show 12 more stories
Why Tempus AI Stock Skyrocketed Nearly 22% TodayThe Motley Fool 4 Analysts Have This To Say About PersonalisBenzinga Cathie Wood's Ark Laps Up $3.3M Worth Of Tesla As Stock Falls For 3rd Straight Session, Sheds Shares Of This Sports Betting CompanyBenzinga Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms CompetitorBenzinga Cathie Wood's Ark Continues Tesla Stock Buying Spree, Acquires Over $14M Worth Of Shares Amid DipBenzinga Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A RecoveryBenzinga Cathie Wood's Ark Invest Isn't Done Selling Shares Of Jack Dorsey-Led Block Yet — Sheds $7.5M Worth of Stock As Bitcoin Price DropsBenzinga Cathie Wood Sells $13.15M Worth Of Coinbase Shares Amid Bitcoin Flirting With All-Time High Levels — Shops For Palantir Stock InsteadBenzinga Lumen Technologies And 2 Other Stocks Under $2 Insiders Are BuyingBenzinga Bausch Health (BHC) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research Personalis (PSNL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research Analyst Ratings for PersonalisBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Discover more
You may be interested in